



REMARKS

Applicant received a Notice to File Missing Parts mailed 3/20/01, wherein it indicated that Figures 5E-F were referenced in the specification, but not supplied with the initial application. Applicant has therefore deleted all references to Figures 5E-F and has attached hereto a formal drawing for Figures 5A-D. Also attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with markings to show changes made".

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 40646-20006.00. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: June 13, 2001

By:

Kate H. Murashige
Kate H. Murashige
Registration No. (29,959)

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

In the Specification:

Figures 5A-5[F] D are graphic representations of responses in serum and nasal mucosa to trivalent split influenza vaccines.

Trivalent proteosome influenza vaccines were prepared using the procedure outlined in Example 3 using detergent split antigens from the A/Beijing/26/95 (H1N1), A/Sydney/05/97 (H3N2) and B/Yamanashi/166/98 sub-types of influenza virus. As shown in Fig. 5A-[F] D for proteosome-flu vaccines made with each strain individually and combining them as a trivalent, strain specific serum IgG (Fig. 5A[,] and C [and E]) and nasal IgA (Fig. 5B[,] D [and E]) responses are enhanced compared to their non-proteosome complexed controls. The immunoglobulin titers induced by the monovalent and trivalent proteosome-flu vaccines are not significantly different. Thus vaccines comprising multivalent influenza antigens induce serum and mucosal immune responses against each component, equivalent to that induced by the individual univalent vaccines.